Mutations of the epidermal growth factor receptor in non-small cell lung cancer – Search and destroy
- 1 January 2006
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 42 (1) , 17-23
- https://doi.org/10.1016/j.ejca.2005.07.031
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Clinically Meaningful Improvement in Symptoms and Quality of Life for Patients With Non-Small-Cell Lung Cancer Receiving Gefitinib in a Randomized Controlled TrialJournal of Clinical Oncology, 2005
- EGFR Mutation Status in Japanese Lung Cancer Patients: Genotyping Analysis Using LightCyclerClinical Cancer Research, 2005
- Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor in Non–Small Cell Lung CancerClinical Cancer Research, 2005
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLoS Medicine, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- EGFR and cancer prognosisPublished by Elsevier ,2001